Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Vera Therapeutics, Inc

VERA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$31.63

▲ +9.48%

Market Cap $2.28B · Vol 1.86M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.28B

Mid Cap

Div Yield

N/A

EPS Growth

-30.81%

YoY

RSI (14)

39.08

Momentum

Beta

0.93

vs Market

52W High

$56.04

43.56% below

52W Low

$21.21

49.13% above

Volume

1.86M

Avg 661.44K

P/B

5.97

Price-to-book

ROE

-50.71%

Return on equity

Free Float

98.56%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Vera Therapeutics, Inc (VERA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VERA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.83%

-26.66%

-20.05%

-25.08%

YTD

-37.54%

+48.71%

+78.80%

+86.72%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-299,615,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-50.71%
ROA · ROIC	-43.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.97
P/FCF	N/A
EPS Growth	-30.81%
Outstanding Shares	72.06M

Technical Indicators

50-Day SMA	$36.17
200-Day SMA	$38.98
RSI (14)	39.08
Beta	0.93
52-Week High	$56.04
52-Week Low	$21.21

Volume Today	1.86M
Avg Daily Volume (30D)	661.44K
Relative Volume	2.81x
Volatility (10D)	74.56
Volatility (30D)	59.50
Free Float	98.56%

Analyst Consensus

BUY

Current Price $31.63

Mean Target $77.23

52W Low$21.21 52W High$56.04

Current

Target

$21.21 $56.04

Current Analyst target

+144.17% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00Q72WYH2

ISINUS92337R1014

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Vera Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.